SELLAS reports FY2025 net loss $26.9M ($0.25/shr); cash $71.8M; Phase 3 REGAL AML trial approaching final analysis

SELLAS Life Sciences Group, Inc.

FY2025 net loss $26.9M ($0.25/shr) vs $30.9M ($0.50/shr) in FY2024; cash $71.8M at Dec 31, 2025.
Received additional $42.6M from warrant exercises in Q1 2026, strengthening balance sheet.
Phase 3 REGAL trial of GPS in AML nearing final analysis at 80 events; 72 events as of Dec 26, 2025.
Phase 2 SLS009 in r/r AML showed 46% ORR; expansion into newly diagnosed AML underway, first patient dosed.
European collaboration with IMPACT-AML to study SLS009 in ~40 newly diagnosed AML patients; enrollment expected Q2 2026.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

SELLAS Life Sciences Group, Inc. reported financial results for the full year ended December 31, 2025.

Period: the full year ended December 31, 2025
Result: reported results

Exact text from the filing

SELLAS Life Sciences Group, Inc. (“SELLAS”) issued a press release (the “Press Release”) announcing its financial results for the year ended December 31, 2025 and providing a corporate update.

View on SEC.gov

168 earnings releases filed in the last 30 days. Browse all earnings releases →

SELLAS Life Sciences Group, Inc. filing history →

Source: SEC EDGAR

accession 0001390478-26-000004

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.